This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

MiMedx Scientific Study To Be Published In The International Wound Journal

Stocks in this article: MDXG

MARIETTA, Ga., July 31, 2013 /PRNewswire/ --  MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that its study "Biological Properties of Dehydrated Human Amnion/Chorion Grafts: Implications for Chronic Wound Healing" has been accepted for publication in the International Wound Journal.  The electronic publication of the study will be available in early August, and the hard copy is expected to be published in the December 2013 edition of the International Wound Journal.

To better understand the mechanisms responsible for the healing qualities of MiMedx dehydrated amnion/chorion membrane allografts (dHACM), the MiMedx research department, led by its Chief Scientific Officer, Thomas Koob, PhD, partnered with researchers from Stanford University School of Medicine and The Georgia Institute of Technology Biotechnology Complex.  Parker H. "Pete" Petit, Chairman and CEO, said, "Fundamentally, the researchers proved, among other things, that our allografts attract critically important regenerative stem cells to the wound site to help repair the wound. In effect, the research confirms that our proprietary PURION® processed allografts act as a "stem cell magnet." 

Bill Taylor, President and Chief Operating Officer, stated, "The research concluded that the MiMedx dHACM allografts positively affect at least four distinct physiological processes critical to wound healing, particularly in chronic wounds. dHACM modulates the inflammatory process, inhibits metalloproteinase activity and matrix degradation, induces regenerative cell proliferation and recruits stem cells. Clearly, multiple factors work in unison to have this kind of impact.  As opposed to a single therapeutic agent, dHACM allografts are a multifaceted, regenerative biomaterial that revitalizes wound healing."

"We will be submitting additional papers that delve deeper into the biological process of our 'stem cell magnet' allografts. These studies involve determining the source of the stem cells, establishing the angiogenic properties of dHACM, and gaining an in depth understanding of various mechanisms of action in wound healing," concluded Petit.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,959.44 +154.64 0.87%
S&P 500 2,078.54 +7.89 0.38%
NASDAQ 4,781.4240 +16.0440 0.34%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs